Tobias Neef1, Stephen D Miller. 1. Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: Current therapies for autoimmune disorders often employ broad suppression of the immune system. Antigen-specific immunotherapy (ASI) seeks to overcome the side-effects of immunosuppressive therapy by specifically targeting only disease-related autoreactive T and B cells. Although it has been in development for several decades, ASI still is not in use clinically to treat autoimmunity. Novel ways to deliver antigen may be effective in inducing ASI. Here we review recent innovations in antigen delivery. RECENT FINDINGS: New ways to deliver antigen include particle and nonparticle approaches. One main focus has been the targeting of antigen-presenting cells in a tolerogenic context. This technique often results in the induction and/or expansion of regulatory T cells, which has the potential to be effective against a complex, polyclonal immune response. SUMMARY: Whether novel delivery approaches can help bring ASI into general clinical use for therapy of autoimmune diseases remains to be seen. However, preclinical work and early results from clinical trials using these new techniques show promising signs.
PURPOSE OF REVIEW: Current therapies for autoimmune disorders often employ broad suppression of the immune system. Antigen-specific immunotherapy (ASI) seeks to overcome the side-effects of immunosuppressive therapy by specifically targeting only disease-related autoreactive T and B cells. Although it has been in development for several decades, ASI still is not in use clinically to treat autoimmunity. Novel ways to deliver antigen may be effective in inducing ASI. Here we review recent innovations in antigen delivery. RECENT FINDINGS: New ways to deliver antigen include particle and nonparticle approaches. One main focus has been the targeting of antigen-presenting cells in a tolerogenic context. This technique often results in the induction and/or expansion of regulatory T cells, which has the potential to be effective against a complex, polyclonal immune response. SUMMARY: Whether novel delivery approaches can help bring ASI into general clinical use for therapy of autoimmune diseases remains to be seen. However, preclinical work and early results from clinical trials using these new techniques show promising signs.
Authors: Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram Journal: Biomaterials Date: 2017-07-24 Impact factor: 12.479
Authors: Jenny Aurielle B Babon; Megan E DeNicola; David M Blodgett; Inne Crèvecoeur; Thomas S Buttrick; René Maehr; Rita Bottino; Ali Naji; John Kaddis; Wassim Elyaman; Eddie A James; Rachana Haliyur; Marcela Brissova; Lut Overbergh; Chantal Mathieu; Thomas Delong; Kathryn Haskins; Alberto Pugliese; Martha Campbell-Thompson; Clayton Mathews; Mark A Atkinson; Alvin C Powers; David M Harlan; Sally C Kent Journal: Nat Med Date: 2016-10-31 Impact factor: 53.440
Authors: Andreas Lutterotti; Sara Yousef; Andreas Sputtek; Klarissa H Stürner; Jan-Patrick Stellmann; Petra Breiden; Stefanie Reinhardt; Christian Schulze; Maxim Bester; Christoph Heesen; Sven Schippling; Stephen D Miller; Mireia Sospedra; Roland Martin Journal: Sci Transl Med Date: 2013-06-05 Impact factor: 17.956
Authors: Derrick P McCarthy; Jonathan Woon-Teck Yap; Christopher T Harp; W Kelsey Song; Jeane Chen; Ryan M Pearson; Stephen D Miller; Lonnie D Shea Journal: Nanomedicine Date: 2016-10-06 Impact factor: 5.307
Authors: Lawrence Steinman; Peggy P Ho; William H Robinson; Paul J Utz; Pablo Villoslada Journal: Curr Opin Immunol Date: 2019-08-30 Impact factor: 7.486
Authors: Farah Arikat; Stephanie J Hanna; Ravinder K Singh; Luciano Vilela; F Susan Wong; Colin M Dayan; Sion A Coulman; James C Birchall Journal: J Control Release Date: 2020-02-19 Impact factor: 9.776
Authors: Dana P Cook; João Paulo Monteiro Carvalho Mori Cunha; Pieter-Jan Martens; Gabriele Sassi; Francesca Mancarella; Giuliana Ventriglia; Guido Sebastiani; An-Sofie Vanherwegen; Mark A Atkinson; Karolien Van Huynegem; Lothar Steidler; Silvia Caluwaerts; Pieter Rottiers; Luc Teyton; Francesco Dotta; Conny Gysemans; Chantal Mathieu Journal: Front Immunol Date: 2020-06-09 Impact factor: 7.561
Authors: Tobias Neef; Igal Ifergan; Sara Beddow; Pablo Penaloza-MacMaster; Kathryn Haskins; Lonnie D Shea; Joseph R Podojil; Stephen D Miller Journal: Cells Date: 2021-12-07 Impact factor: 7.666